Screener / SEC EDGAR /CIK 0000009326 /10-K filed Feb 20, 2026, compared with Feb 21, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Materials · Chemicals & Allied Products

Balchem Corp BCPC

Compare with peers Embed
Earnings releases

Latest results release: Oct 23, 2026

8-K item 2.02, exhibit 99

What BCPC's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Feb 20, 2026, BCPC reported $4.75 per share under GAAP and $5.15 on its own adjusted basis: the adjusted number is +8% above GAAP.

GAAP EPS $0.98, release Jul 26, 2024: GAAP earnings per share of $0.98 compared to $0.93 in the prior year quarter and record adjusted earnings per share (a) of $1.09 compared to $1.06 in the prior year quarter. Adjusted EPS $1.09, release Jul 26, 2024: GAAP earnings per share of $0.98 compared to $0.93 in the prior year quarter and record adjusted earnings per share (a) of $1.09 compared to $1.06 in the prior year quarter. +11% 2024-07 GAAP EPS $1.03, release Oct 25, 2024: GAAP earnings per share of $1.03 compared to $0.90 in the prior year quarter and record adjusted earnings per share (a) of $1.13 compared to $1.04 in the prior year quarter. Adjusted EPS $1.13, release Oct 25, 2024: GAAP earnings per share of $1.03 compared to $0.90 in the prior year quarter and record adjusted earnings per share (a) of $1.13 compared to $1.04 in the prior year quarter. +10% 2024-10 GAAP EPS $3.93, release Feb 21, 2025: These net earnings resulted in GAAP earnings per share of $3.93 compared to $3.35 in the prior year. Adjusted EPS $4.37, release Feb 21, 2025: These adjusted net earnings resulted in adjusted earnings per share of $4.37 compared to $4.00 in the prior year. +11% 2025-02 GAAP EPS $1.17, release Jul 31, 2025: GAAP earnings per share of $1.17 compared to $0.98 in the prior year quarter and record adjusted earnings per share (a) of $1.27 compared to $1.09 in the prior year quarter. Adjusted EPS $1.27, release Jul 31, 2025: GAAP earnings per share of $1.17 compared to $0.98 in the prior year quarter and record adjusted earnings per share (a) of $1.27 compared to $1.09 in the prior year quarter. +8% 2025-07 GAAP EPS $1.24, release Oct 21, 2025: GAAP earnings per share of $1.24 compared to $1.03 in the prior year quarter and record adjusted earnings per share (a) of $1.35 compared to $1.13 in the prior year quarter. Adjusted EPS $1.35, release Oct 21, 2025: GAAP earnings per share of $1.24 compared to $1.03 in the prior year quarter and record adjusted earnings per share (a) of $1.35 compared to $1.13 in the prior year quarter. +9% 2025-10 GAAP EPS $4.75, release Feb 20, 2026: These net earnings resulted in record GAAP earnings per share of $4.75 compared to $3.93 in the prior year. Adjusted EPS $5.15, release Feb 20, 2026: These adjusted net earnings resulted in record adjusted earnings per share of $5.15 compared to $4.37 in the prior year. +8% 2026-02
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
The company's words, latest release
These net earnings resulted in record GAAP earnings per share of $4.75 compared to $3.93 in the prior year. release
These adjusted net earnings resulted in record adjusted earnings per share of $5.15 compared to $4.37 in the prior year. release

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 23, 2026 · EX-99.1

Human Nutrition & Health | Animal Nutrition &

Open on SEC

Exhibit 99.1 Human Nutrition & Health | Animal Nutrition & Health | Specialty Products

Balchem Corporation Reports Third Quarter 2026 Financial Results Montvale, NJ, October 23, 2026 - Balchem Corporation (NASDAQ: BCPC) today reported financial results for its 2026 fiscal third quarter ended September 30, 2026. For the quarter, the Company reported net sales of $290.7 million, net earnings of $46.7 million, adjusted EBITDA (a) of $80.3 million, and free c ash flow (a) of $57.9 million.

Ted Harris, Chairman, President and CEO of Balchem, said, “Balchem delivered another excellent quarter, with healthy growth across all three of our reporting segments and record consolidated quarterly net sales, net earnings, and adjusted EBITDA.”

• Net sales were $290.7 million, an increase of 8.6% from the prior year quarter.

• GAAP net earnings were $46.7 million, an increase of 16.0% from the prior year quarter.

• Adjusted EBITDA was $80.3 million, an increase of 12.4% from the prior year quarter.

• GAAP earnings per share were $1.46 compared to $1.24 in the prior year quarter and adjusted earnings per share (a) were $1.57 compared to $1.35 in the prior year quarter.

• Cash flows from operations were $69.8 million, with free cash flow of $57.9 million.

• Sales and earnings from operations growth in all three of our reporting segments.

• At the upcoming SupplySide Global trade show, we will showcase several of our latest Human Nutrition and Health technologies and innovations, including new science supporting VitaCholine ® , K2VITAL ™ , Optifolin+ ® and OptiMSM ® , as well as advances in performance nutrition and functional food and beverage applications. These innovations highlight the strength of our pipeline and our continued focus on developing differentiated, science-backed solutions that address important human health and wellness trends.

• Balchem repurchased approximately $28 million of common stock during the third quarter and approximately $127 million over the trailing twelve months, reflecting the Company's balanced capital allocation strategy and commitment to long-term shareholder value creation.

Mr. Harris added, “With strong results through the first nine months of the year and a healthy balance sheet, Balchem is well positioned to continue executing our strategic growth initiatives, and we remain excited about the future of our company.”

(a) See “Non-GAAP Financial Information” for a reconciliation of GAAP and non-GAAP financial measures.

segment generated record quarterly sales of $188.2 million, an increase of $14.1 million, or 8.1%, compared to the prior year quarter. The increase was driven by higher sales within both the nutrients business and the food ingredients and solutions businesses. Record earnings from operations for this segment of $45.6 million increased $4.8 million, or 11.8%, compared to $40.8 million in the prior year quarter, primarily due to the aforementioned higher sales and favorable mix, partially offset by higher operating expenses. Excluding the effect of non- cash expense associated with amortization of acquired intangible assets and other adjustments, record adjusted earnings from operations (a) for this segment were $48.9 million, compared to $44.1 million in the prior year quarter, an increase of 10.9%.

segment generated quarterly sales of $63.0 million, an increase of $6.6 million, or 11.7%, compared to the prior year quarter. The increase was driven by higher sales in both the monogastric and ruminant species markets. Third quarter earnings from operations for this segment of $6.8 million increased $3.1 million, or 82.8%, compared to $3.7 million in the prior year quarter, primarily due to the aforementioned higher sales and favorable mix, partially offset by certain higher manufacturing input costs. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, adjusted earnings from operations for this segment were $7.0 million compared to $4.0 million in the prior year quarter, an increase of 73.6%.

segment generated quarterly sales of $37.3 million, an increase of $1.6 million, or 4.5%, compared to the prior year quarter, due to higher sales in the performance gases business. Earnings from operations for this segment of $12.3 million increased $0.8 million, or 6.6%, compared to $11.5 million in the prior year quarter, primarily driven by the aforementioned higher sales and favorable mix, partially offset by higher operating expenses. Excluding the effect of non- cash expense associated with amortization of acquired intangible assets and other adjustments, adjusted earnings from operations for this segment were $13.1 million, compared to $12.7 million in the prior year quarter, an increase of 3.0%.

Consolidated quarterly gross margin of $105.7 million increased by $10.3 million, or 10.7%, compared to $95.5 million for the prior year comparable period. Gross margin as a percentage of sales was 36.4% compared to 35.7% in the prior year period, an increase of 70 basis points, primarily due to sales growth, favorable mix and manufacturing efficiencies, partially offset by certain higher manufacturing input costs. Operating expenses of $43.3 million for the quarter increased $2.4 million from the prior year comparable quarter, primarily due to higher compensation-related costs, partially offset by the net favorable impact of certain discrete items.

Net interest expense was $1.9 million and $2.6 million in the third quarters of 2026 and 2025, respectively. The decrease in interest expense was primarily due to lower outstanding borrowings and lower interest rates. Our effective tax rates for the three months ended September 30, 2026 and 2025 were 22.2% a nd 22.6%, respectively . The decrease in the effective tax rate was primarily d ue to higher favorable adjustments related to the filing of the prior year federal tax return and a higher foreign-derived intangible income deduction benefit, partially offset by an increase in certain state taxes.

Third quarter cash flows provided by operating activities were $69.8 million and free cash flow was $57.9 million. Net working capital of $240.8 million as of September 30, 2026 included a cash balance of $66.3 million. Significant cash payments during the quarter included net debt payments of $28.0 million, income taxes paid of $27.8 million, repurchases of common stock of $27.4 million, and capital expenditures and intangible assets acquired of $12.5 million. Outstanding debt on our revolving loan was $124.0 million as of September 30, 2026 and our net debt (b) was $57.7 million, with an overall leverage ratio (c) on a net debt basis of 0.2 times.

Mr. Harris said, “The Balchem team delivered another strong quarter in Q3 of 2026, and we remain confident in the long-term growth outlook for our company as we continue to execute our strategic growth initiatives.”

(b) Net debt is defined as the outstanding balance on our revolving loan less cash and cash equivalents. (c) Leverage ratio is defined as net debt divided by trailing twelve months adjusted EBITDA.

A quarterly conference call will be held on Friday, October 23, 2026, at 11:00 AM Eastern Time (ET) to review third quarter 2026 results. Ted Harris, Chairman, President and CEO and Martin Bengtsson, CFO, will host the call. Institutional investors, analysts and other members of the financial community are invited to join the live call by dialing +1-833-461-5787 (USA/Canada toll free) or +1-585-542-9983 (International Toll), and referencing Meeting ID: 831870284, five minutes prior to the scheduled start time of the conference call. Investors and the public are invited to listen to the live webcast at https://events.q4inc.com/attendee/831870284. The conference call will be available for replay shortly after the conclusion of the call at https://events.q4inc.com/attendee/831870284 for one year.

Balchem Corporation reports three business segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition and Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition and Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged performance gases for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".

This release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. Forward-looking statements may relate to such matters as projections of revenue, margins, expenses, tax provisions, earnings, cash flows, benefit obligations, dividends, share repurchases or other financial items; any statements of the plans, strategies and objectives of management for future operations, including those relating to any statements concerning expected development, performance or market share relating to our products and services; any statements regarding future economic conditions or our performance; any statements regarding pending investigations, claims or disputes; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. These statements are based on the Company's currently available information and our current assumptions, expectations and projections about future events. They are subject to future events, risks and uncertainties - many of which are beyond the Company’s control - as well as potentially inaccurate assumptions, that could cause actual results to differ materially from those in the forward-looking statements. Important factors and other risks that may affect the Company's business or that could cause actual results to differ materially are included in filings the Company makes with the U.S. Securities and Exchange Commission from time to time, including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, its Current Reports on Form 8-K, and in its other SEC filings. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact: Jacqueline Yarmolowicz, Balchem Corporation (Telephone: 845-326-5600)

Nine Months Ended Cash flows from September 30, operating activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net earnings $ 131,628 $ 115,620 Adjustments to reconcile net earnings to net cash provided by operating activities: Depreciation and 37,100 33,969 amortization Stock compensation 16,316 14,298 expense Other adjustments 3,037 -1,692 Changes in assets and -31,537 -12,914 liabilities Net cash provided by operating 156,544 149,281 activities Cash flows from investing activities: Capital expenditures and intangible -29,605 -27,275 assets acquired Cash paid for acquisitions, net of — -323 cash acquired Proceeds from the sale 7 267 of assets Investment in -155 -144 affiliates Net cash used in -29,753 -27,475 investing activities Cash flows from financing activities: Proceeds from 88,000 70,000 revolving loan Principal payments on -128,000 -106,000 revolving loan Principal payments on -153 -145 finance leases Cash paid for -1,943 — financing costs Proceeds from stock 11,589 6,867 options exercised Dividends paid -30,773 -28,276 Repurchases of common -71,925 -54,008 stock Net cash used in -133,205 -111,562 financing activities Effect of exchange -1,892 5,334 rate changes on cash (Decrease) increase in cash and cash -8,306 15,578 equivalents Cash and cash equivalents, beginning 74,570 49,515 of period Cash and cash equivalents, end of $ 66,264 $ 65,093 period

In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted diluted per share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, free cash flow, net debt, and leverage ratio. The non-GAAP financial measures disclosed by the Company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain equity compensation, nonqualified deferred compensation plan expense (income), and certain one-time or unusual transactions. Detailed non-GAAP adjustments are described in the reconciliation tables below and also explained in the related footnotes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Investors should not consider non-GAAP measures as alternatives to the related GAAP measures.

Set forth below are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

(unaudited) Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income Tax Rate

(1)Amortization of intangible assets and finance leases: Amortization of intangible assets and finance leases consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets, capitalized loan issuance costs, other intangibles acquired primarily in connection with business combinations, and finance leases. We record expense relating to the amortization of these intangibles and finance leases in our GAAP financial statements. Amortization expenses for our intangible assets and finance leases are inconsistent in amount and are significantly impacted by the timing and valuation of acquisitions. Consequently, our non-GAAP adjustments exclude these expenses to facilitate an evaluation of our current operating performance and comparisons to our past operating performance. (2)Transaction and integration costs: Transaction and integration costs related to acquisitions and divestitures are expensed in our GAAP financial statements. Management excludes these items for the purposes of calculating adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with transactions that are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. (3)Nonqualified deferred compensation plan (income) expense: Gains and losses on rabbi trust assets related to our nonqualified deferred compensation plan are recorded in other (income) expense while the offsetting increases or decreases to the deferred compensation liability are recorded within earnings from operations. The increases and decreases in the deferred compensation liability are driven by market volatility and are not a true reflection of company performance. We believe excluding these amounts from our non-GAAP financial measures is useful to investors because these items are inconsistent in amount based on market conditions causing comparison of current and historical financial results to be difficult. (4)Restructuring costs: Restructuring costs related to a reorganization of the business are recorded in our GAAP financial statements. Management excludes these items for the purposes of calculating adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these items are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. (5)Income tax adjustment: For purposes of calculating adjusted net earnings and adjusted diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the taxable and deductible non-GAAP adjustments described above as they have a significant impact on our income tax (benefit) provision. Additionally, the income tax adjustment is adjusted for the impact of adopting ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” and uses our non-GAAP effective rate applied to both our GAAP earnings before income tax expense and non-GAAP adjustments described above. See Table 3 for the calculation of our non-GAAP effective tax rate. (6)Impact of ASU 2016-09: The primary impact of ASU No. 2016-09, "Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), was the recognition during the three and nine months ended September 30, 2026 and 2025, of excess tax benefits as a reduction to the provision for income taxes and the classification of these excess tax benefits in operating activities in the consolidated statement of cash flows instead of financing activities. Management excludes this item for the purpose of calculating adjusted Income Tax Expense. We believe that excluding the item in our non-GAAP financial measures is useful to investors because it is inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult.

Full text with the tables
                                                                 
                                                   Exhibit 99.1  
  Human Nutrition & Health | Animal Nutrition &                  
  Health | Specialty Products                                    
                                                                 
        Balchem Corporation Reports Third Quarter 2026 Financial Results        
Montvale, NJ, October 23, 2026 - Balchem Corporation (NASDAQ: BCPC) today
reported financial results for its 2026 fiscal third quarter ended September 30,
2026. For the quarter, the Company reported net sales of $290.7 million, net
earnings of $46.7 million, adjusted EBITDA (a) of $80.3 million, and free c ash
flow (a) of $57.9 million.

Ted Harris, Chairman, President and CEO of Balchem, said, “Balchem delivered
another excellent quarter, with healthy growth across all three of our reporting
segments and record consolidated quarterly net sales, net earnings, and adjusted
EBITDA.”

Third Quarter 2026 Financial Highlights:

• Net sales were $290.7 million, an increase of 8.6% from the prior year
quarter.

• GAAP net earnings were $46.7 million, an increase of 16.0% from the prior year
quarter.

• Adjusted EBITDA was $80.3 million, an increase of 12.4% from the prior year
quarter.

• GAAP earnings per share were $1.46 compared to $1.24 in the prior year quarter
and adjusted earnings per share (a) were $1.57 compared to $1.35 in the prior
year quarter.

• Cash flows from operations were $69.8 million, with free cash flow of $57.9
million.

• Sales and earnings from operations growth in all three of our reporting
segments.

Recent Highlights:

• At the upcoming SupplySide Global trade show, we will showcase several of our
latest Human Nutrition and Health technologies and innovations, including new
science supporting VitaCholine ® , K2VITAL ™ , Optifolin+ ® and OptiMSM ® , as
well as advances in performance nutrition and functional food and beverage
applications. These innovations highlight the strength of our pipeline and our
continued focus on developing differentiated, science-backed solutions that
address important human health and wellness trends.

• Balchem repurchased approximately $28 million of common stock during the third
quarter and approximately $127 million over the trailing twelve months,
reflecting the Company's balanced capital allocation strategy and commitment to
long-term shareholder value creation.

Mr. Harris added, “With strong results through the first nine months of the year
and a healthy balance sheet, Balchem is well positioned to continue executing
our strategic growth initiatives, and we remain excited about the future of our
company.”
                                         
  5 Paragon Drive        p.845.326.5600  
  Montvale, NJ  07645    f.845.326.5702  
  balchem.com                            
                                         
Balchem Corporation (NASDAQ:BCPC)
                                                                                
            Results for Period Ended September 30, 2026 (unaudited)             
                                                                                
                 (Dollars in thousands, except per share data)                  
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net        $     290,658    $     267,558    $      845,364    $     773,544  
  sales                                                                         
  Gross            105,714           95,453           310,481          276,734  
  margin                                                                        
  Operat…           43,277           40,874           133,197          119,698  
  expens…                                                                       
  Earnin…                                                                       
  from              62,437           54,579           177,284          157,036  
  operat…                                                                       
  Intere…                                                                       
  and                2,393            2,535             6,937            8,041  
  other                                                                         
  expens…                                                                       
  Earnin…                                                                       
  before                                                                        
  income            60,044           52,044           170,347          148,995  
  tax                                                                           
  expense                                                                       
  Income                                                                        
  tax               13,316           11,755            38,719           33,375  
  expense                                                                       
  Net        $      46,728    $      40,289    $      131,628    $     115,620  
  earnin…                                                                       
  Diluted                                                                       
  net                                                                           
  earnin…    $        1.46    $        1.24    $         4.09    $        3.54  
  per                                                                           
  common                                                                        
  share                                                                         
  Adjust…    $      80,297    $      71,447    $      232,522    $     206,961  
  EBITDA…                                                                       
  Adjust…                                                                       
  net        $      50,350    $      43,982    $      141,437    $     125,560  
  earnin…                                                                       
  Adjust…                                                                       
  net                                                                           
  earnin…    $        1.57    $        1.35    $         4.40    $        3.84  
  per                                                                           
  common                                                                        
  share(…                                                                       
  Shares                                                                        
  used in                                                                       
  the                                                                           
  calcul…                                                                       
  of                                                                            
  diluted                                                                       
  and               32,032           32,595            32,181           32,702  
  adjust…                                                                       
  net                                                                           
  earnin…                                                                       
  per                                                                           
  common                                                                        
  share                                                                         
                                                                                
                                                                                
  (a)    See “Non-GAAP Financial Information” for a reconciliation of GAAP and  
         non-GAAP financial measures.                                           
                                                                                
            
  Page | 2  
            
Balchem Corporation (NASDAQ:BCPC)

Financial Results for the Third Quarter of 2026:
The
                                                                                
  Human Nutrition and Health                                                    
                                                                                
segment generated record quarterly sales of $188.2 million, an increase of $14.1
million, or 8.1%, compared to the prior year quarter. The increase was driven by
higher sales within both the nutrients business and the food ingredients and
solutions businesses. Record earnings from operations for this segment of $45.6
million increased $4.8 million, or 11.8%, compared to $40.8 million in the prior
year quarter, primarily due to the aforementioned higher sales and favorable
mix, partially offset by higher operating expenses. Excluding the effect of non-
cash expense associated with amortization of acquired intangible assets and
other adjustments, record adjusted earnings from operations (a) for this segment
were $48.9 million, compared to $44.1 million in the prior year quarter, an
increase of 10.9%.

The
                                                                                
  Animal Nutrition and Health                                                   
                                                                                
segment generated quarterly sales of $63.0 million, an increase of $6.6 million,
or 11.7%, compared to the prior year quarter. The increase was driven by higher
sales in both the monogastric and ruminant species markets. Third quarter
earnings from operations for this segment of $6.8 million increased $3.1
million, or 82.8%, compared to $3.7 million in the prior year quarter, primarily
due to the aforementioned higher sales and favorable mix, partially offset by
certain higher manufacturing input costs. Excluding the effect of non-cash
expense associated with amortization of acquired intangible assets and other
adjustments, adjusted earnings from operations for this segment were $7.0
million compared to $4.0 million in the prior year quarter, an increase of
73.6%.

The
                                                                                
  Specialty Products                                                            
                                                                                
segment generated quarterly sales of $37.3 million, an increase of $1.6 million,
or 4.5%, compared to the prior year quarter, due to higher sales in the
performance gases business. Earnings from operations for this segment of $12.3
million increased $0.8 million, or 6.6%, compared to $11.5 million in the prior
year quarter, primarily driven by the aforementioned higher sales and favorable
mix, partially offset by higher operating expenses. Excluding the effect of non-
cash expense associated with amortization of acquired intangible assets and
other adjustments, adjusted earnings from operations for this segment were $13.1
million, compared to $12.7 million in the prior year quarter, an increase of
3.0%.

Consolidated quarterly gross margin of $105.7 million increased by $10.3
million, or 10.7%, compared to $95.5 million for the prior year comparable
period. Gross margin as a percentage of sales was 36.4% compared to 35.7% in the
prior year period, an increase of 70 basis points, primarily due to sales
growth, favorable mix and manufacturing efficiencies, partially offset by
certain higher manufacturing input costs. Operating expenses of $43.3 million
for the quarter increased $2.4 million from the prior year comparable quarter,
primarily due to higher compensation-related costs, partially offset by the net
favorable impact of certain discrete items.

Net interest expense was $1.9 million and $2.6 million in the third quarters of
2026 and 2025, respectively. The decrease in interest expense was primarily due
to lower outstanding borrowings and lower interest rates. Our effective tax
rates for the three months ended September 30, 2026 and 2025 were 22.2% a nd
22.6%, respectively . The decrease in the effective tax rate was primarily d ue
to higher favorable adjustments related to the filing of the prior year federal
tax return and a higher foreign-derived intangible income deduction benefit,
partially offset by an increase in certain state taxes.

Third quarter cash flows provided by operating activities were $69.8 million and
free cash flow was $57.9 million. Net working capital of $240.8 million as of
September 30, 2026 included a cash balance of $66.3 million. Significant cash
payments during the quarter included net debt payments of $28.0 million, income
taxes paid of $27.8 million, repurchases of common stock of $27.4 million, and
capital expenditures and intangible assets acquired of $12.5 million.
Outstanding debt on our revolving loan was $124.0 million as of September 30,
2026 and our net debt (b) was $57.7 million, with an overall leverage ratio (c)
on a net debt basis of 0.2 times.

Mr. Harris said, “The Balchem team delivered another strong quarter in Q3 of
2026, and we remain confident in the long-term growth outlook for our company as
we continue to execute our strategic growth initiatives.”
                                                                                
  (b)    Net debt is defined as the outstanding balance on our revolving loan   
         less cash and cash equivalents.                                        
  (c)    Leverage ratio is defined as net debt divided by trailing twelve       
         months adjusted EBITDA.                                                
                                                                                
            
  Page | 3  
            
Balchem Corporation (NASDAQ:BCPC)
                                                                                
  Quarterly Conference Call                                                     
                                                                                
A quarterly conference call will be held on Friday, October 23, 2026, at 11:00
AM Eastern Time (ET) to review third quarter 2026 results. Ted Harris, Chairman,
President and CEO and Martin Bengtsson, CFO, will host the call. Institutional
investors, analysts and other members of the financial community are invited to
join the live call by dialing +1-833-461-5787 (USA/Canada toll free) or
+1-585-542-9983 (International Toll), and referencing Meeting ID: 831870284,
five minutes prior to the scheduled start time of the conference call. Investors
and the public are invited to listen to the live webcast at
https://events.q4inc.com/attendee/831870284. The conference call will be
available for replay shortly after the conclusion of the call at
https://events.q4inc.com/attendee/831870284 for one year.
                                                                                
  Segment Information                                                           
                                                                                
Balchem Corporation reports three business segments: Human Nutrition and Health,
Animal Nutrition and Health, and Specialty Products. The Human Nutrition and
Health segment delivers customized food and beverage ingredient systems, as well
as key nutrients into a variety of applications across the food, supplement and
pharmaceutical industries. The Animal Nutrition and Health segment manufactures
and supplies products to numerous animal health markets. Through Specialty
Products, Balchem provides specialty-packaged performance gases for use in
healthcare and other industries, and also provides chelated minerals to the
micronutrient agricultural market. Sales and production of products outside of
our reportable segments and other minor business activities are included in
"Other and Unallocated".
                                                                                
  Forward-Looking Statements                                                    
                                                                                
This release contains forward-looking statements, within the meaning of the
Private Securities Litigation Reform Act of 1995, Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended,
which reflect our expectation or belief concerning future events that involve
risks and uncertainties. These forward-looking statements generally are
identified by the words "believe," "project," "expect," "anticipate,"
"estimate," "forecast," "outlook," "intend," "strategy," "future,"
"opportunity," "plan," "may," "should," "will," "would," "will be," "will
continue," "will likely result," or the negative thereof or variations thereon
or similar expressions generally intended to identify forward-looking
statements. Forward-looking statements may relate to such matters as projections
of revenue, margins, expenses, tax provisions, earnings, cash flows, benefit
obligations, dividends, share repurchases or other financial items; any
statements of the plans, strategies and objectives of management for future
operations, including those relating to any statements concerning expected
development, performance or market share relating to our products and services;
any statements regarding future economic conditions or our performance; any
statements regarding pending investigations, claims or disputes; any statements
of expectation or belief; and any statements of assumptions underlying any of
the foregoing. These statements are based on the Company's currently available
information and our current assumptions, expectations and projections about
future events. They are subject to future events, risks and uncertainties - many
of which are beyond the Company’s control - as well as potentially inaccurate
assumptions, that could cause actual results to differ materially from those in
the forward-looking statements. Important factors and other risks that may
affect the Company's business or that could cause actual results to differ
materially are included in filings the Company makes with the U.S. Securities
and Exchange Commission from time to time, including its Annual Report on Form
10-K, its Quarterly Reports on Form 10-Q, its Current Reports on Form 8-K, and
in its other SEC filings. Reference should be made to such factors and all
forward-looking statements are qualified in their entirety by the above
cautionary statements. The Company undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact: Jacqueline Yarmolowicz, Balchem Corporation (Telephone: 845-326-5600)
            
  Page | 4  
            
Balchem Corporation (NASDAQ:BCPC)
                                                                                
  Selected Financial Data (unaudited)                                           
                                                                                
($ in 000’s)
                                                                                
                        Three                             Nine                  
         Busin…        Months                           Months                  
         Segme…         Ended                            Ended                  
         Net           Septe…                          Septem…                  
         Sales:  2026     30,    2025            2026      30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Human                                                                         
  Nutr…          $     188,2…    $     174,0…    $     536,749    $     493,3…  
  and                                                                           
  Heal…                                                                         
  Anim…                                                                         
  Nutr…                62,990          56,376          189,633          169,6…  
  and                                                                           
  Heal…                                                                         
  Spec…                37,294          35,683          112,532          106,1…  
  Prod…                                                                         
  Othe…                 2,147           1,411            6,450           4,402  
  Total          $     290,6…    $     267,5…    $     845,364    $     773,5…  
  (d)O…                                                                         
  cons…                                                                         
  of a                                                                          
  few                                                                           
  minor                                                                         
  busi…                                                                         
  which                                                                         
  indi…                                                                         
  do                                                                            
  not                                                                           
  meet                                                                          
  the                                                                           
  quan…                                                                         
  thre…                                                                         
  for                                                                           
  sepa…                                                                         
  pres…                                                                         
                                                                                
                                                                                
         Busin…                                                                 
         Segme…         Three                             Nine                  
         Earni…        Months                           Months                  
         Before         Ended                            Ended                  
         Income        Septe…                          Septem…                  
         Taxes:  2026     30,    2025            2026      30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Human                                                                         
  Nutr…          $     45,633    $     40,831    $     128,034    $     117,1…  
  and                                                                           
  Heal…                                                                         
  Anim…                                                                         
  Nutr…                 6,789           3,713           17,708          12,463  
  and                                                                           
  Heal…                                                                         
  Spec…                12,301          11,534           37,129          32,388  
  Prod…                                                                         
  Other                                                                         
  and                  -2,286          -1,499           -5,587          -4,962  
  Unal…                                                                         
  Inte…                                                                         
  and                  -2,393          -2,535           -6,937          -8,041  
  other                                                                         
  expe…                                                                         
  Total          $     60,044    $     52,044    $     170,347    $     148,9…  
  (e)O…                                                                         
  and                                                                           
  Unal…                                                                         
  cons…                                                                         
  of a                                                                          
  few                                                                           
  minor                                                                         
  busi…                                                                         
  which                                                                         
  indi…                                                                         
  do                                                                            
  not                                                                           
  meet                                                                          
  the                                                                           
  quan…                                                                         
  thre…                                                                         
  for                                                                           
  sepa…                                                                         
  pres…                                                                         
  and                                                                           
  corp…                                                                         
  expe…                                                                         
  that                                                                          
  have                                                                          
  not                                                                           
  been                                                                          
  allo…                                                                         
  to                                                                            
  a                                                                             
  segm…                                                                         
  Unal…                                                                         
  corp…                                                                         
  expe…                                                                         
  cons…                                                                         
  of                                                                            
  tran…                                                                         
  and                                                                           
  inte…                                                                         
  cost…                                                                         
  $578                                                                          
  and                                                                           
  $1,4…                                                                         
  three                                                                         
  and                                                                           
  nine                                                                          
  mont…                                                                         
  ended                                                                         
  Sept…                                                                         
  30,                                                                           
  2026,                                                                         
  resp…                                                                         
  and                                                                           
  $333                                                                          
  and                                                                           
  $1,2…                                                                         
  for                                                                           
  the                                                                           
  three                                                                         
  and                                                                           
  nine                                                                          
  mont…                                                                         
  ended                                                                         
  Sept…                                                                         
  30,                                                                           
  2025,                                                                         
  resp…                                                                         
                                                                                
            
  Page | 5  
            
Balchem Corporation (NASDAQ:BCPC)
                                                                                
  Selected                                                                      
  Balance Sheet  (Dollars in                September 30,         December 31,  
  Items          thousands)                          2026                 2025  
 ────────────────────────────────────────────────────────────────────────────── 
                              -unaudited                                        
  Cash and cash               $                    66,264    $          74,570  
  equivalents                                                                   
  Accounts                                                                      
  receivable,                                     145,635              143,596  
  net                                                                           
  Inventories                                     177,006              131,449  
  Other current                                    15,972               15,999  
  assets                                                                        
  Total current                                   404,877              365,614  
  assets                                                                        
  Property,                                                                     
  plant and                                       306,135              306,648  
  equipment,                                                                    
  net                                                                           
  Goodwill                                        807,487              816,375  
  Intangible                                                                    
  assets with                                     147,366              163,289  
  finite lives,                                                                 
  net                                                                           
  Right of use                                     17,683               16,192  
  assets                                                                        
  Other assets                                     20,024               18,134  
  Total                                                                         
  non-current                                   1,298,695            1,320,638  
  assets                                                                        
  Total assets                $                 1,703,572    $       1,686,252  
  Current                     $                   164,115    $         176,384  
  liabilities                                                                   
  Revolving                                       124,000              164,000  
  loan                                                                          
  Deferred                                         52,273               54,143  
  income taxes                                                                  
  Other                                                                         
  long-term                                        36,407               34,312  
  obligations                                                                   
  Total                                           376,795              428,839  
  liabilities                                                                   
  Stockholders'                                 1,326,777            1,257,413  
  equity                                                                        
  Total                                                                         
  liabilities                                                                   
  and                         $                 1,703,572    $       1,686,252  
  stockholders'                                                                 
  equity                                                                        
                                                                                
            
  Page | 6  
            
Balchem Corporation (NASDAQ:BCPC)
                                                                                
                              Balchem Corporation                               
                                                                                
                                                                                
                Condensed Consolidated Statements of Cash Flows                 
                                                                                
                             (Dollars in thousands)                             
(unaudited)
                                                                                
                            Nine Months Ended                                   
  Cash flows from           September 30,                                       
  operating activities:     2026                                2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net earnings              $                        131,628    $      115,620  
  Adjustments to                                                                
  reconcile net earnings                                                        
  to net cash provided                                                          
  by operating                                                                  
  activities:                                                                   
  Depreciation and                                    37,100            33,969  
  amortization                                                                  
  Stock compensation                                  16,316            14,298  
  expense                                                                       
  Other adjustments                                    3,037            -1,692  
  Changes in assets and                              -31,537           -12,914  
  liabilities                                                                   
  Net cash provided by                                                          
  operating                                          156,544           149,281  
  activities                                                                    
  Cash flows from                                                               
  investing activities:                                                         
  Capital expenditures                                                          
  and intangible                                     -29,605           -27,275  
  assets acquired                                                               
  Cash paid for                                                                 
  acquisitions, net of                                     —              -323  
  cash                                                                          
  acquired                                                                      
  Proceeds from the sale                                   7               267  
  of assets                                                                     
  Investment in                                         -155              -144  
  affiliates                                                                    
  Net cash used in                                   -29,753           -27,475  
  investing activities                                                          
  Cash flows from                                                               
  financing activities:                                                         
  Proceeds from                                       88,000            70,000  
  revolving loan                                                                
  Principal payments on                             -128,000          -106,000  
  revolving loan                                                                
  Principal payments on                                 -153              -145  
  finance leases                                                                
  Cash paid for                                       -1,943                 —  
  financing costs                                                               
  Proceeds from stock                                 11,589             6,867  
  options exercised                                                             
  Dividends paid                                     -30,773           -28,276  
  Repurchases of common                              -71,925           -54,008  
  stock                                                                         
  Net cash used in                                  -133,205          -111,562  
  financing activities                                                          
  Effect of exchange                                  -1,892             5,334  
  rate changes on cash                                                          
  (Decrease) increase in                                                        
  cash and cash                                       -8,306            15,578  
  equivalents                                                                   
  Cash and cash                                                                 
  equivalents, beginning                              74,570            49,515  
  of                                                                            
  period                                                                        
  Cash and cash                                                                 
  equivalents, end of       $                         66,264    $       65,093  
  period                                                                        
                                                                                
            
  Page | 7  
            
Balchem Corporation (NASDAQ:BCPC)
                                                                                
  Non-GAAP Financial Information                                                
                                                                                
In addition to disclosing financial results in accordance with United States
(U.S.) generally accepted accounting principles (GAAP), this earnings release
contains non-GAAP financial measures that we believe are helpful in
understanding and comparing our past financial performance and our future
results. The non-GAAP financial measures in this press release include adjusted
gross margin, adjusted earnings from operations, adjusted net earnings and the
related adjusted diluted per share amounts, EBITDA, adjusted EBITDA, adjusted
income tax expense, free cash flow, net debt, and leverage ratio. The non-GAAP
financial measures disclosed by the Company exclude certain business combination
accounting adjustments and certain other items related to acquisitions, certain
equity compensation, nonqualified deferred compensation plan expense (income),
and certain one-time or unusual transactions. Detailed non-GAAP adjustments are
described in the reconciliation tables below and also explained in the related
footnotes. These non-GAAP financial measures should not be considered a
substitute for, or superior to, financial measures calculated in accordance with
GAAP, and the financial results calculated in accordance with GAAP and
reconciliations from these results should be carefully evaluated. Investors
should not consider non-GAAP measures as alternatives to the related GAAP
measures.

Set forth below are reconciliations of the non-GAAP financial measures to the
most directly comparable GAAP financial measures.
                                                                                
  Table 1                                                                       
                                                                                
(unaudited)
                                                                                
                  Reconciliation of Non-GAAP Measures to GAAP                   
                                                                                
                 (Dollars in thousands, except per share data)                  
                                                                                
            Three                              Nine                             
  Recon…    Months                             Months                           
  of        Ended                              Ended                            
  adjus…    Septe…                             Septe…                           
  gross     30,                                30,                              
  margin    2026               2025            2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  gross     $       105,714    $     95,453    $       310,481    $     276,7…  
  margin                                                                        
  Amort…                                                                        
  of                                                                            
  intan…                                                                        
  assets                715             739              2,162           2,156  
  and                                                                           
  finan…                                                                        
  lease…                                                                        
  Adjus…                                                                        
  gross     $       106,429    $     96,192    $       312,643    $     278,8…  
  margin                                                                        
  Recon…                                                                        
  of                                                                            
  adjus…                                                                        
  earni…                                                                        
  from                                                                          
  opera…                                                                        
  GAAP                                                                          
  earni…    $        62,437    $     54,579    $       177,284    $     157,0…  
  from                                                                          
  opera…                                                                        
  Amort…                                                                        
  of                                                                            
  intan…                                                                        
  assets              4,333           4,394             13,137          12,819  
  and                                                                           
  finan…                                                                        
  lease…                                                                        
  Trans…                                                                        
  and                   578             333              1,495           1,227  
  integ…                                                                        
  costs…                                                                        
  Nonqu…                                                                        
  defer…                                                                        
  compe…                -45             404                572             839  
  plan                                                                          
  expen…                                                                        
  Restr…                  —               —                  —            -192  
  costs…                                                                        
  Adjus…                                                                        
  earni…    $        67,303    $     59,710    $       192,488    $     171,7…  
  from                                                                          
  opera…                                                                        
  Recon…                                                                        
  of                                                                            
  adjus…                                                                        
  net                                                                           
  earni…                                                                        
  GAAP                                                                          
  net       $        46,728    $     40,289    $       131,628    $     115,6…  
  earni…                                                                        
  Amort…                                                                        
  of                                                                            
  intan…                                                                        
  assets              4,433           4,467             13,381          13,035  
  and                                                                           
  finan…                                                                        
  lease…                                                                        
  Trans…                                                                        
  and                   578             333              1,495           1,227  
  integ…                                                                        
  costs…                                                                        
  Restr…                  —               —                  —            -192  
  costs…                                                                        
  Income                                                                        
  tax                -1,389          -1,107             -5,067          -4,130  
  adjus…                                                                        
  Adjus…                                                                        
  net       $        50,350    $     43,982    $       141,437    $     125,5…  
  earni…                                                                        
  Adjus…                                                                        
  net                                                                           
  earni…                                                                        
  per       $          1.57    $       1.35    $          4.40    $       3.84  
  common                                                                        
  share                                                                         
  -                                                                             
  dilut…                                                                        
                                                                                
            
  Page | 8  
            
Balchem Corporation (NASDAQ:BCPC)
                                                                                
  Table 2                                                                       
                                                                                
(unaudited)
      Reconciliation of GAAP Net Earnings to EBITDA and to Adjusted EBITDA      
                                                                                
                             (Dollars in thousands)                             
                                                                                
               Th…                                 Nine                         
               Mo…                                 Mon…                         
               En…                                 End…                         
               Se…                                 Sep…                         
        20…    30,         20…              20…    30,          2025            
 ────────────────────────────────────────────────────────────────────────────── 
  N…                                                                            
  e…                                                                            
  -            $    46…           $  40…           $     13…            $  11…  
  as                                                                            
  r…                                                                            
  A…                                                                            
  b…                                                                            
  P…                                                                            
  f…                13…              11…                 38…               33…  
  i…                                                                            
  t…                                                                            
  I…                                                                            
  a…                2,…              2,…                 6,…               8,…  
  o…                                                                            
  e…                                                                            
  D…                                                                            
  a…                12…              11…                 36…               33…  
  a…                                                                            
  E…                74…              66…                 21…               19…  
  A…                                                                            
  b…                                                                            
  N…                                                                            
  c…                                                                            
  e…                                                                            
  r…                5,…              4,…                 16…               14…  
  to                                                                            
  e…                                                                            
  a…                                                                            
  T…                                                                            
  a…                578              333                 1,…               1,…  
  i…                                                                            
  c…                                                                            
  N…                                                                            
  d…                                                                            
  c…                -45              404                 572               839  
  p…                                                                            
  e…                                                                            
  R…                  —                —                   —               -1…  
  c…                                                                            
  A…           $    80…           $  71…           $     23…            $  20…  
  E…                                                                            
                                                                                
                                                                                
  Table 3                                                                       
                                                                                
(unaudited)
 Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income  
                                    Tax Rate                                    
                                                                                
                             (Dollars in thousands)                             
                                                                                
                 Thr…                                                           
                 Mon…                                                           
                 End…         Eff…                              Eff…            
                 Sep…         Tax                               Tax             
         2026    30,          Rate            2025              Rate            
 ────────────────────────────────────────────────────────────────────────────── 
  GA…                                                                           
  In…            $     13…            22…  %          $  11…            22…  %  
  Tax                                                                           
  Ex…                                                                           
  Im…                                                                           
  of                   260                                21                    
  ASU                                                                           
  20…                                                                           
  Ad…                                                                           
  In…            $     13…            22…  %          $  11…            22…  %  
  Tax                                                                           
  Ex…                                                                           
                                                                                
                                                                                
                 Nine                                                           
                 Mon…                                                           
                 End…         Eff…                              Eff…            
                 Sep…         Tax                               Tax             
         2026    30,          Rate            2025              Rate            
 ────────────────────────────────────────────────────────────────────────────── 
  GA…                                                                           
  In…            $     38…            22…  %          $  33…            22…  %  
  Tax                                                                           
  Ex…                                                                           
  Im…                                                                           
  of                   1,…                               894                    
  ASU                                                                           
  20…                                                                           
  Ad…                                                                           
  In…            $     40…            23…  %          $  34…            23…  %  
  Tax                                                                           
  Ex…                                                                           
                                                                                
            
  Page | 9  
            
Balchem Corporation (NASDAQ:BCPC)
                                                                                
  Table 4                                                                       
                                                                                
(unaudited)
 Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow  
                                                                                
                             (Dollars in thousands)                             
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  cash                                                                          
  provid…    $      69,772    $      65,572    $      156,544    $     149,281  
  by                                                                            
  operat…                                                                       
  activi…                                                                       
  Capital                                                                       
  expend…                                                                       
  and                                                                           
  procee…          -11,863          -14,891           -28,559          -26,866  
  from                                                                          
  the                                                                           
  sale of                                                                       
  assets                                                                        
  Free                                                                          
  cash       $      57,909    $      50,681    $      127,985    $     122,415  
  flow                                                                          
                                                                                
                                                      
  (1)Amortization of intangible assets and finance    
  leases:                                             
  Amortization of intangible assets and finance       
  leases consists of amortization of customer         
  relationships, trademarks and trade names,          
  developed technology, regulatory registration       
  costs, patents and trade secrets, capitalized loan  
  issuance costs, other intangibles acquired          
  primarily in connection with business               
  combinations, and finance leases. We record         
  expense relating to the amortization of these       
  intangibles and finance leases in our GAAP          
  financial statements. Amortization expenses for     
  our intangible assets and finance leases are        
  inconsistent in amount and are significantly        
  impacted by the timing and valuation of             
  acquisitions. Consequently, our non-GAAP            
  adjustments exclude these expenses to facilitate    
  an evaluation of our current operating performance  
  and comparisons to our past operating performance.  
  (2)Transaction and integration costs: Transaction   
  and integration costs related to acquisitions and   
  divestitures are expensed in our GAAP financial     
  statements. Management excludes these items for     
  the purposes of calculating adjusted EBITDA and     
  other non-GAAP financial measures. We believe that  
  excluding these items from our non-GAAP financial   
  measures is useful to investors because these are   
  items associated with transactions that are         
  inconsistent in amount and frequency causing        
  comparison of current and historical financial      
  results to be difficult.                            
  (3)Nonqualified deferred compensation plan          
  (income) expense: Gains and losses on rabbi trust   
  assets related to our nonqualified deferred         
  compensation plan are recorded in other (income)    
  expense while the offsetting increases or           
  decreases to the deferred compensation liability    
  are recorded within earnings from operations. The   
  increases and decreases in the deferred             
  compensation liability are driven by market         
  volatility and are not a true reflection of         
  company performance. We believe excluding these     
  amounts from our non-GAAP financial measures is     
  useful to investors because these items are         
  inconsistent in amount based on market conditions   
  causing comparison of current and historical        
  financial results to be difficult.                  
  (4)Restructuring costs: Restructuring costs         
  related to a reorganization of the business are     
  recorded in our GAAP financial statements.          
  Management excludes these items for the purposes    
  of calculating adjusted EBITDA and other non-GAAP   
  financial measures. We believe that excluding       
  these items from our non-GAAP financial measures    
  is useful to investors because these items are      
  inconsistent in amount and frequency causing        
  comparison of current and historical financial      
  results to be difficult.                            
  (5)Income tax adjustment:                           
  For purposes of calculating adjusted net earnings   
  and adjusted diluted earnings per share, we adjust  
  the provision for (benefit from) income taxes to    
  tax effect the taxable and deductible non-GAAP      
  adjustments described above as they have a          
  significant impact on our income tax (benefit)      
  provision. Additionally, the income tax adjustment  
  is adjusted for the impact of adopting ASU          
  2016-09, “Improvements to Employee Share-Based      
  Payment Accounting” and uses our non-GAAP           
  effective rate applied to both our GAAP earnings    
  before income tax expense and non-GAAP adjustments  
  described above. See Table 3 for the calculation    
  of our non-GAAP effective tax rate.                 
  (6)Impact of ASU 2016-09:                           
  The primary impact of ASU No. 2016-09,              
  "Improvements to Employee Share-Based Payment       
  Accounting" ("ASU 2016-09"), was the recognition    
  during the three and nine months ended September    
  30, 2026 and 2025, of excess tax benefits as a      
  reduction to the provision for income taxes and     
  the classification of these excess tax benefits in  
  operating activities in the consolidated statement  
  of cash flows instead of financing activities.      
  Management excludes this item for the purpose of    
  calculating adjusted Income Tax Expense. We         
  believe that excluding the item in our non-GAAP     
  financial measures is useful to investors because   
  it is inconsistent in amount and frequency causing  
  comparison of current and historical financial      
  results to be difficult.                            
                                                      
             
  Page | 10  
             

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCPC/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.